Related Experiment Video

Updated: Jul 4, 2026

Hyperinsulinemic-euglycemic Clamps in Conscious, Unrestrained Mice
11:10

Hyperinsulinemic-euglycemic Clamps in Conscious, Unrestrained Mice

Published on: November 16, 2011

The effects of GLP-1 analogues on pre-diabetes of the children

Qing-Xia Zhou1, Zi-Yu Wang2, Hua-Feng Zhao1

  • 1Department of Pediatrics, Weifang People's Hospital, Weifang, Shandong 261041, P.R. China.

Experimental and Therapeutic Medicine
|April 18, 2017
PubMed

Insights

Glucagon-like peptide-1 (GLP-1) analogues effectively manage pre-diabetes in children. This intervention improved blood sugar, lipid profiles, BMI, insulin resistance, and islet cell function, offering a new treatment approach.

Area of Science:

  • Pediatric Endocrinology
  • Metabolic Disorders
  • Pharmacological Interventions

Background:

  • Pre-diabetes in children poses a significant risk for developing type 2 diabetes.
  • Early intervention strategies are crucial to prevent disease progression.
  • Glucagon-like peptide-1 (GLP-1) analogues have shown promise in adult metabolic regulation.

Purpose of the Study:

  • To assess the efficacy of GLP-1 analogues in pediatric pre-diabetes.
  • To determine if GLP-1 analogues can delay or reverse pre-diabetes progression.
  • To evaluate the impact of GLP-1 analogues on key metabolic markers in children.

Main Methods:

  • A prospective, randomized controlled trial involving 42 children with newly diagnosed pre-diabetes.
  • Participants were divided into two groups: lifestyle intervention (control) and lifestyle intervention plus GLP-1 analogue (liraglutide).
  • Interventions lasted 3 months, with assessments at 1 and 3 months, measuring fasting blood glucose, HbA1c, lipid profiles, BMI, insulin resistance, and islet cell function.

Main Results:

  • The GLP-1 analogue group showed significantly better control of fasting and postprandial blood glucose levels after 1 and 3 months compared to the control group.
  • Improvements were observed in HbA1c, total cholesterol, triglycerides, LDL-C, HDL-C, and BMI in the GLP-1 analogue group.
  • The GLP-1 analogue group demonstrated a significant decrease in insulin resistance and an increase in islet β-cell function.

Conclusions:

  • GLP-1 analogues are effective in regulating blood sugar in children with pre-diabetes.
  • These analogues improve lipid profiles, body mass, insulin resistance, and islet β-cell function.
  • GLP-1 analogues represent a novel therapeutic avenue for early intervention in pediatric pre-diabetes.

Keywords:
GLP-1 analogueschildrenliraglutidepre-diabetes

More Related Videos

Homogeneous Time-resolved Förster Resonance Energy Transfer-based Assay for Detection of Insulin Secretion07:30

Homogeneous Time-resolved Förster Resonance Energy Transfer-based Assay for Detection of Insulin Secretion

Published on: May 10, 2018

Mechanisms Underlying Gut Hormone Secretion Using the Isolated Perfused Rat Small Intestine07:00

Mechanisms Underlying Gut Hormone Secretion Using the Isolated Perfused Rat Small Intestine

Published on: February 26, 2019

Related Concept Videos

Diabetes Mellitus: Type 2 and Gestational01:22

Diabetes Mellitus: Type 2 and Gestational

Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are typically...
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...